Jenni Murray's HRT question: Can you take hormone therapy after breast cancer? Doctors explain

In February 2026, Dame Jenni Murray — the journalist and former BBC Radio 4 Woman's Hour presenter who had breast cancer approximately 20 years ago — publicly revealed she intends to ask her GP to prescribe hormone replacement therapy (HRT), including testosterone, despite her cancer history. "I have ageing bones and muscles, and I want my energy and mood back," she told the Daily Mail. Her candid disclosure has reignited a debate in UK medical circles: who, exactly, can safely take HRT after breast cancer — and what should patients actually discuss with their doctor?

What does current UK medical guidance say about HRT after breast cancer?

The short answer is: it depends on the type of breast cancer and the specific hormones involved.

The British Menopause Society (BMS) and the National Institute for Health and Care Excellence (NICE) both maintain nuanced positions. For most women with a history of oestrogen-receptor-positive (ER+) breast cancer — the most common type, accounting for roughly 75-80% of all cases — systemic oestrogen-based HRT is generally contraindicated. The reasoning is straightforward: ER+ tumours are fuelled by oestrogen, and reintroducing it may increase the risk of recurrence.

However, the picture is more complex for:

• Women with ER-negative breast cancer: NICE acknowledges that HRT may be an option in cases where symptoms are severe and standard non-hormonal treatments have failed.
• Testosterone: The evidence base is less clear. A 2023 NICE review noted that testosterone cream or gel — used primarily for low libido and mood — is not systemically absorbed at the same levels as oestrogen and may carry a different risk profile. Some specialists at NHS menopause clinics now prescribe it on a case-by-case basis to women with cancer histories, with close monitoring.
• Local (vaginal) oestrogen: Low-dose topical oestrogen for vaginal dryness and urinary symptoms has much lower systemic absorption than oral or transdermal HRT. The Royal College of Obstetricians and Gynaecologists considers it broadly safe for most breast cancer survivors, including those on aromatase inhibitors.

Jenni Murray, who has said she no longer has measurable residual oestrogen following post-menopausal changes, believes the hormonal risk calculus has shifted for her. Whether her GP agrees will depend on her full medical history, the type of breast cancer she had, and any ongoing treatment.

The GP conversation: what to bring and what to ask

The question of HRT after breast cancer is not one to resolve via a web search. It is, at its core, a personalised medical risk assessment — and one that GPs are increasingly equipped to handle following the 2022 expansion of NHS menopause training and the updated NICE menopause guidance published in November 2024.

If you are in a similar position to Jenni Murray — post-menopausal, with a cancer history, experiencing symptoms that affect your quality of life — here is what doctors recommend bringing to the conversation:

1. Your pathology report or cancer summary: The key detail is whether your cancer was ER-positive, ER-negative, or HER2-positive, as this directly affects which HRT options are possible.
2. A record of current medications: Some cancer treatments (particularly aromatase inhibitors like letrozole or anastrozole) interact directly with oestrogen-based HRT, making co-prescription inappropriate.
3. A symptom diary: Noting which symptoms are affecting daily life — sleep, mood, joint pain, cognition, libido, urinary function — helps the GP prioritise the most disruptive issues and match them to the safest targeted interventions.
4. Your preferences on risk tolerance: There is no universally "correct" answer. For some women, a marginal increase in statistical recurrence risk is acceptable given the severity of their quality-of-life symptoms; for others, it is not. The BMS encourages shared decision-making.

Beyond HRT: what other options exist for managing post-cancer menopause?

For women who are not candidates for systemic HRT, UK doctors and oncologists typically recommend a stepped approach:

• Non-hormonal prescription options: SSRIs (particularly venlafaxine at low dose) and gabapentin have evidence for reducing hot flushes. Clonidine, an older option, is less commonly used but still available.
• CBT-based programmes: The NHS currently funds "Menopause Mindfulness" and similar cognitive behavioural therapy programmes specifically designed for hot flush management. A 2022 trial at King's College London found a 50% reduction in hot flush frequency after 6 sessions.
• Lifestyle modifications: Regular aerobic exercise, reducing caffeine and alcohol, and maintaining a cool sleep environment have robust evidence for symptom reduction in menopausal women.
• Testosterone (low dose): As noted above, this remains an option some specialist NHS menopause clinics will consider separately from oestrogen-based HRT.

When to see a specialist rather than your GP

For straightforward menopause consultations, a GP with menopause training is the right starting point. However, the British Menopause Society recommends referral to a specialist menopause clinic when:

• There is a history of cancer, particularly breast, ovarian, or endometrial cancer
• Standard treatments have failed or caused intolerable side effects
• There is significant medical complexity (cardiovascular disease, osteoporosis, prior DVT/PE)
• The patient has a query about surgical menopause following oophorectomy under the age of 45

Specialist menopause clinics are available on the NHS (via GP referral) and privately. In the private sector, a single consultation with a menopause specialist typically costs between £150 and £350 and provides a detailed, personalised treatment plan.

For women who want faster access to a qualified doctor — whether a GP with menopause experience or a specialist — platforms like Expert Zoom allow you to book a Health consultation online, with verified practitioners available within hours.

Important: This article provides general health information only and does not constitute medical advice. Decisions about HRT or other hormone therapy — particularly with a cancer history — must be made with a qualified healthcare professional who has access to your full medical history.

Dame Jenni Murray's question is one that thousands of UK women over 60 are asking. The answer is never simple — but the conversation with a doctor is always the right starting point.